Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  lorlatinib
Find trials that include:  Any drugs shown
Results 1-4 of 4 for your search:
Start Over
A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: B7461001, NCI-2014-00522, 2013-002620-17, NCT01970865
Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: B9991005, NCI-2015-01886, 2015-001879-43, NCT02584634
ALK/ROS1 Inhibitor PF-06463922 in Treating Patients with Advanced ALK and ROS1 Rearranged Metastatic Non-small Cell Lung Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 16-248, NCI-2016-01859, NCT02927340
Study of Lorlatinib (PF-06463922)
Status: Not yet active
Phase: Phase I
Type: Treatment
Age: 1 to 90
Trial IDs: N2015-02, NCI-2017-00943, NCT03107988
Start Over